RIGEL PHARMACEUTICALS INC
RIGL · XNASCIK 1034842fmd_10FX836DSHY9W5ANPJXX43TMF5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 20 | 4 | 45 | 59 | 109 | 149 | 120 | 117 | 179 | 294 |
| Cost of revenue | – | – | 0 | 1 | 1 | 1 | 2 | 7 | 19 | 20 |
| Gross profit | – | – | 44 | 58 | 108 | 148 | 118 | 110 | 161 | 275 |
| Research and development | 63 | 46 | 47 | 53 | 60 | 65 | 60 | 25 | 23 | 33 |
| Selling, general and administrative | 21 | 38 | 70 | 75 | 77 | 92 | 112 | 106 | 113 | 116 |
| Operating income | (70) | (80) | (73) | (69) | (29) | (12) | (56) | (20) | 24 | 125 |
| Interest expense | – | – | – | 0 | 1 | 5 | 4 | 7 | 8 | 7 |
| Interest and investment income | 0 | 1 | 2 | 3 | 1 | 0 | 1 | 2 | 2 | 4 |
| Income before taxes | – | – | – | (67) | (30) | (17) | (59) | (25) | 18 | 122 |
| Income tax expense | 0 | 0 | 0 | – | – | 1 | – | 0 | 1 | (245) |
| Net income from continuing operations | – | – | – | – | – | (18) | – | (25) | 17 | 367 |
| Net income | (69) | (78) | (70) | (67) | (30) | (18) | (59) | (25) | 17 | 367 |
| Net income to common shareholders | (69) | (78) | (70) | (67) | (30) | (18) | (59) | (25) | 17 | 367 |